Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$78.54 USD
+0.19 (0.24%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $78.52 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Balance Sheet
Fiscal Year End for Dr Reddy's Laboratories Ltd falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 979 | 767 | 610 | 490 | 356 |
Receivables | 963 | 882 | 880 | 679 | 667 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 763 | 592 | 671 | 621 | 465 |
Other Current Assets | 271 | 277 | 236 | 238 | 241 |
Total Current Assets | 2,976 | 2,518 | 2,397 | 2,027 | 1,729 |
Net Property & Equipment | 923 | 809 | 819 | 781 | 694 |
Investments & Advances | 63 | 65 | 105 | 114 | 41 |
Other Non-Current Assets | 0 | 0 | 1 | 2 | 23 |
Deferred Charges | 129 | 88 | 108 | 145 | 162 |
Intangibles | 494 | 427 | 417 | 549 | 420 |
Deposits & Other Assets | 65 | 10 | 12 | 11 | 11 |
Total Assets | 4,650 | 3,916 | 3,860 | 3,630 | 3,081 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 371 | 322 | 337 | 325 | 221 |
Current Portion Long-Term Debt | 169 | 148 | 370 | 328 | 276 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 28 | 26 | 21 | 19 | 8 |
Other Current Liabilities | 586 | 548 | 510 | 468 | 461 |
Total Current Liabilities | 1,152 | 1,044 | 1,239 | 1,140 | 966 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 11 | 10 | 1 | 5 | 4 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 72 | 16 | 76 | 86 | 17 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 49 | 36 | 33 | 33 | 38 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,284 | 1,106 | 1,348 | 1,264 | 1,025 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 10 | 10 | 11 | 11 | 11 |
Capital Surplus | 129 | 118 | 122 | 122 | 113 |
Retained Earnings | 3,183 | 2,623 | 2,316 | 2,133 | 1,913 |
Other Equity | 56 | 75 | 82 | 127 | 31 |
Treasury Stock | 12 | 15 | 21 | 27 | 13 |
Total Shareholder's Equity | 3,366 | 2,810 | 2,511 | 2,366 | 2,056 |
Total Liabilities & Shareholder's Equity | 4,650 | 3,916 | 3,860 | 3,630 | 3,081 |
Total Common Equity | 3,366 | 2,810 | 2,511 | 2,366 | 2,056 |
Shares Outstanding | 166.80 | 166.50 | 166.40 | 166.20 | 165.70 |
Book Value Per Share | 20.18 | 16.88 | 15.09 | 14.24 | 12.41 |
Fiscal Year End for Dr Reddy's Laboratories Ltd falls in the month of March.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,141 | 979 | 877 | 827 | 756 |
Receivables | 973 | 963 | 943 | 839 | 939 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 823 | 763 | 731 | 681 | 639 |
Other Current Assets | 294 | 271 | 318 | 274 | 228 |
Total Current Assets | 3,230 | 2,976 | 2,867 | 2,620 | 2,562 |
Net Property & Equipment | 964 | 923 | 875 | 848 | 819 |
Investments & Advances | 63 | 63 | 100 | 71 | 60 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 179 | 129 | 131 | 130 | 116 |
Intangibles | 497 | 494 | 496 | 497 | 516 |
Deposits & Other Assets | 51 | 65 | 14 | 10 | 10 |
Total Assets | 4,984 | 4,650 | 4,482 | 4,178 | 4,084 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 409 | 371 | 374 | 367 | 337 |
Current Portion Long-Term Debt | 293 | 169 | 164 | 86 | 93 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 58 | 28 | 50 | 48 | 54 |
Other Current Liabilities | 508 | 586 | 536 | 512 | 501 |
Total Current Liabilities | 1,268 | 1,152 | 1,125 | 1,013 | 984 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 57 | 11 | 12 | 1 | 8 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 75 | 72 | 74 | 73 | 60 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 48 | 51 | 44 | 42 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,448 | 1,284 | 1,262 | 1,131 | 1,094 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 10 | 10 | 10 | 10 | 10 |
Capital Surplus | 130 | 129 | 129 | 128 | 120 |
Retained Earnings | 3,351 | 3,183 | 3,030 | 2,867 | 2,803 |
Other Equity | 57 | 56 | 62 | 53 | 71 |
Treasury Stock | 12 | 12 | 12 | 12 | 14 |
Total Shareholder's Equity | 3,536 | 3,366 | 3,220 | 3,047 | 2,990 |
Total Liabilities & Shareholder's Equity | 4,984 | 4,650 | 4,482 | 4,178 | 4,084 |
Total Common Equity | 3,536 | 3,366 | 3,220 | 3,047 | 2,990 |
Shares Outstanding | 166.80 | 166.80 | 166.80 | 166.80 | 166.60 |
Book Value Per Share | 21.20 | 20.18 | 19.30 | 18.27 | 17.95 |